HOOKIPA Pharma to Present at Upcoming Conferences in May
April 29 2020 - 7:00AM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapeutics targeting infectious diseases and
cancers based on its proprietary arenavirus platform, today
announced that HOOKIPA’s management team will participate in the
following virtual investor conferences in May:
- SunTrust Robinson Humphrey 6th Annual Life Sciences Summit, May
5 - 6, 2020
- Bank of America Global Research Health Care Conference 2020,
May 12 - 14, 2020
- RBC Capital Markets Global Healthcare Conference, May 19 - 20,
2020, including a webcast presentation at 8:00 a.m. ET on May
19
The live audio webcast of the presentation held
at the RBC Capital Markets Global Healthcare Conference will be
available within the Investors & Media section of HOOKIPA’s
website at https://ir.hookipapharma.com/events. An archived replay
will be accessible for 30 days following the event.
About
HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical
stage biopharmaceutical company developing a new class of
immunotherapeutics targeting infectious diseases and cancers based
on its proprietary arenavirus platform that is designed to
reprogram the body’s immune system.
HOOKIPA’s proprietary arenavirus-based
technologies, VaxWave®, a replication-deficient viral vector, and
TheraT®, a replication-attenuated viral vector, are designed to
induce robust antigen specific CD8+ T cells and
pathogen-neutralizing antibodies. Both technologies are designed to
allow for repeat administration to augment and refresh immune
responses. TheraT® has the potential to induce CD8+ T cell response
levels previously not achieved by other immuno-therapy approaches.
HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in
vivo to activate the immune system.
HOOKIPA’s VaxWave®-based prophylactic
Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2
clinical trial in CMV-negative patients awaiting kidney
transplantation from living CMV-positive donors as well as
CMV-positive patients awaiting kidney transplantation from
CMV-positive or -negative donors. To expand its infectious disease
portfolio, HOOKIPA has entered into a collaboration and licensing
agreement with Gilead Sciences, Inc. to jointly research and
develop functional cures for HIV and chronic Hepatitis B
infections.
In addition, HOOKIPA is building a proprietary
immuno-oncology pipeline by targeting virally mediated cancer
antigens, self-antigens and next-generation antigens. The TheraT®
based lead oncology product candidates, HB-201 and HB-202, are in
development for the treatment of Human Papilloma Virus16-positive
cancers. The Phase 1/2 clinical trial for HB-201 was initiated in
December 2019. The HB-202 IND submission is intended for the first
half of 2020.
Find out more about HOOKIPA online at
www.hookipapharma.com.
HOOKIPA Forward Looking
Statements
Certain statements set forth in this press
release constitute “forward-looking” statements within the meaning
of the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements can be identified by terms such
as “believes,” “expects,” “plans,” “potential,” “would” or similar
expressions and the negative of those terms. Such forward-looking
statements involve substantial risks and uncertainties that could
cause HOOKIPA’s research and clinical development programs, future
results, performance or achievements to differ significantly from
those expressed or implied by the forward-looking statements. Such
risks and uncertainties include, among others, the uncertainties
inherent in the drug development process, including HOOKIPA’s
programs’ early stage of development, the process of designing and
conducting preclinical and clinical trials, the regulatory approval
processes, the timing of regulatory filings, the challenges
associated with manufacturing drug products, HOOKIPA’s ability to
successfully establish, protect and defend its intellectual
property, risks relating to business interruptions resulting from
the coronavirus (COVID-19) disease outbreak or similar public
health crises and other matters that could affect the sufficiency
of existing cash to fund operations and HOOKIPA’s ability to
achieve the milestones under the agreement with Gilead. HOOKIPA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of the company in general, see HOOKIPA’s
annual report on Form 10-K for the full year ended December 31,
2019 which is on the Security and Exchange Commission’s website at
www.sec.gov and HOOKIPA’s website at
www.hookipapharma.com.
Investors and others should note that we announce material
financial information to our investors using our investor relations
website (https://ir.hookipapharma.com/), SEC filings, press
releases, public conference calls and webcasts. We use these
channels, as well as social media, to communicate with our members
and the public about our company, our services and other issues. It
is possible that the information we post on social media could be
deemed to be material information. Therefore, we encourage
investors, the media, and others interested in our company to
review the information we post on the U.S. social media channels
listed on our investor relations website.
For further information, please contact:
Media |
Investors |
Nina Waibel |
Matt Beck |
Senior Director - Communications |
Executive Director - Investor Relations |
nina.waibel@hookipapharma.com |
matthew.beck@hookipapharma.com |
|
|
Media enquiries |
|
Instinctif Partners |
|
hookipa@instinctif.com |
|
+44 (0)20 7457 2020 |
|
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Apr 2023 to Apr 2024